PEMAZYRE — Total revenues
Incyte PEMAZYRE — Total revenues decreased by 3.5% to $22.54M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.3%, from $18.44M to $22.54M. Over 4 years (FY 2021 to FY 2025), PEMAZYRE — Total revenues shows an upward trend with a 6.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration or expanded clinical adoption, while a decrease may signal increased competition, loss of patent exclusivity, or market saturation.
Detailed definition
This metric represents the total gross revenue generated from the commercial sale of a specific oncology therapeutic pro...
Peer comparison
Comparable to product-specific net sales reported by other biopharmaceutical companies for their key oncology or specialty drug assets.
incy_segment_pemazyre_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17.91M | $17.56M | $19.61M | $18.03M | $18.98M | $23.41M | $23.02M | $22.48M | $21.57M | $18.94M | $20.65M | $17.68M | $20.27M | $20.66M | $23.14M | $18.44M | $22.19M | $22.74M | $23.35M | $22.54M |
| QoQ Change | — | -1.9% | +11.6% | -8.0% | +5.3% | +23.3% | -1.7% | -2.4% | -4.0% | -12.2% | +9.0% | -14.4% | +14.7% | +1.9% | +12.0% | -20.3% | +20.3% | +2.5% | +2.7% | -3.5% |
| YoY Change | — | — | — | — | +6.0% | +33.3% | +17.4% | +24.6% | +13.6% | -19.1% | -10.3% | -21.4% | -6.0% | +9.1% | +12.1% | +4.3% | +9.5% | +10.1% | +0.9% | +22.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's pemazyre — total revenues?
- Incyte (INCY) reported pemazyre — total revenues of $22.54M in Q1 2026.
- How has Incyte's pemazyre — total revenues changed year-over-year?
- Incyte's pemazyre — total revenues increased by 22.3% year-over-year, from $18.44M to $22.54M.
- What is the long-term trend for Incyte's pemazyre — total revenues?
- Over 4 years (2021 to 2025), Incyte's pemazyre — total revenues has grown at a 6.1% compound annual growth rate (CAGR), from $68.53M to $86.73M.
- What does pemazyre — total revenues mean?
- The total sales revenue generated by a specific pharmaceutical product.